PARP-Inhibitor Combination Treatments Grant

Pfizer Inc. has issued a Request for Proposals (RFP) as part of its Independent Medical Education (IME) grant program focused on enhancing healthcare professional competence in the treatment of metastatic prostate cancer (mPC). Released on June 26, 2025, this RFP specifically invites proposals on the topic “PARP-Inhibitor Combination Treatments: Biomarker Testing, Safety, and Efficacy in a Rapidly Changing Metastatic Prostate Cancer (mPC) Landscape.” This initiative is part of Pfizer’s ongoing efforts to support projects aligned with its scientific strategy through its External Research & Grants (ER&G) office, which oversees independent initiatives designed to improve patient outcomes in areas of unmet medical need. The grant opportunity aims to fund educational projects that promote knowledge in several key areas: appropriate integration and interpretation of biomarker and genetic mutation testing in clinical practice, emerging data on PARP inhibitors (PARPi) in the treatment of mPC, best practices for initiating guideline-concordant care, and strategies for overcoming barriers to genetic testing in community healthcare settings. Emphasis is placed on the role of the multidisciplinary team in ordering, interpreting, and managing test results and therapies, as well as engaging patients in clinical trials and shared decision-making. Acceptable educational formats under this RFP include live conference sessions, multi-company supported symposia, expert interviews, online articles, webinars, social media content, and multimedia tools such as videos and podcasts. Clinical research projects, or those evaluating the efficacy of therapeutic or diagnostic agents, will not be considered for funding. The target audience includes community oncologists, urologists, oncology nurses and nurse practitioners, physician assistants, pharmacists, and genetic counselors. Pfizer anticipates a total grant budget of $850,000 for this RFP, with individual grants capped at $350,000, inclusive of direct costs and institutional overhead (capped at 28%). Multi-supported educational programs are encouraged. Key dates include a submission deadline of August 21, 2025, with award notifications expected the week of September 15, 2025. Approved projects are anticipated to start in October 2025 and conclude by April 2027, with a maximum project duration of 18 months. Applications must be submitted through the Pfizer CyberGrants portal at www.cybergrants.com/pfizer/knowledge. Applicants should select “2025 ONC US PARPi mCRPC IME” as the Competitive Grant Program Name and “Oncology – Genitourinary - KG” as the Primary Area of Interest. Only U.S.-based organizations are eligible to apply. These may include accredited healthcare institutions, professional schools, medical education companies, and other nonprofits focused on health education or improvement. Projects involving multiple institutions must identify the requesting organization as the lead with a relevant role. Applicants must upload a detailed proposal document addressing objectives, needs assessment, audience, project design, innovation, evaluation, dissemination, timeline, and budget narrative. The proposal should be single-spaced, in 12-point Calibri font, with 1-inch margins, and not exceed 15 pages, excluding references. Additional questions should be directed to Lori Carpenter at lori.carpenter@pfizer.com with the subject “2025 ONC US PARPi mCRPC IME.” Applications received after the deadline will not be reviewed, and Pfizer will not accept modifications to its grant agreement terms unless legally required.